- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01808391
A Prospective Multicenter Post Approval Study to Evaluate the Long-term Safety and Efficacy of the Resolute Integrity in the Japanese All-comers Patients With Coronary Artery Disease (PROPEL)
A Prospective Multicenter Post Approval Study to Evaluate the Long-term Safety and Efficacy of the Resolute Integrity in the Japanese All-comers Patients With Coronary Artery Disease
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Minato-ku, Tokyo, Japan, 105-0013
- Non-profit organization Associations for Establishment of Evidence in Interventions
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients aged 20 years or older.
- Patients with symptomatic coronary disease.
- Patients with a clinical indication for PCI and stenting of at least one coronary lesion, visually confirmed on coronary angiography.
- Patients who give informed consent to participate in this clinical study and sign the informed consent form approved by the institutional review board of each study site before the index PCI.
- Patients who agree to undergo all clinical follow-up procedures specified in the protocol for this clinical study.
- Patients in whom more than 50% occlusion or stenosis is visually confirmed in a native coronary artery with a diameter of 2.5 mm - 3.5 mm on coronary angiography and that has an anatomical structure suitable for PCI using Resolute Integrity zotarolimus-eluting stent.
Exclusion Criteria:
- Patients aged 85 years or older.
- Patients with cardiogenic shock.
- Patients who are pregnant or possibly pregnant.
- Patients who cannot comply with the antiplatelet therapy specified for this clinical study.
- Patients scheduled to undergo elective surgery within 6 months post-index PCI.
- Patients with a history of allergic reaction or hypersensitivity to zotarolimus, sirolimus, tacrolimus, everolimus, or other analogues or derivatives.
- Patients with an allergic reaction to antiplatelet or anticoagulant drugs, such as heparin, aspirin, ticlopidine, or clopidogrel, or contrast agents, or those who cannot tolerate these substances and to whom appropriate treatments cannot be given.
- Patients with hypersensitivity to cobalt, nickel, chrome, molybdenum, coated polymer (e.g., BioLinx) contained in the materials of the study device or in whom these substances are specifically contraindicated.
- Patients who are currently participating in a clinical study of another drug or medical device and in whom assessment of the primary endpoint of that study has not been completed or clinically interferes with the endpoints of this clinical study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Clinical Follow-up Cohort
The clinical FU cohort comprises among patients who underwent clinical FU at 9, 12, and 24 months after index PCI those who arbitrarily underwent angiographic FU at 22 months (±60 days) after index PCI and those who did not undergo angiographic follow-up at all during the entire study period.
|
Routine Angiographic Follow-up Cohort
The routine angiographic FU cohort comprises patients who underwent clinical FU at 9, 12, and 24 months after index PCI those who undergo angiographic FU at 10 months (±60 days) after index PCI.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TLF (target lesion failure)
Time Frame: 12 months
|
The composite of Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel) or Target Lesion Revascularization (TLR; clinically indicated) (= device oriented endpoint).
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Delivery success
Time Frame: stent implantation until hospital discharge (average 1-5 days)
|
Complete passage of the stent across the target lesion with full expansion of the stent to the desired diameter at the desired location. Note: Failed delivery: failure to pass the stent through the guiding catheter into the coronary artery,failure to pass it completely across the target lesion, or failure to expand the stent to its desired diameter. Failed delivery includes proximal deployment defined as those instances of failed delivery when the stent could be advanced only partially across the target lesion but was deployed nonetheless by full expansion. |
stent implantation until hospital discharge (average 1-5 days)
|
Lesion success
Time Frame: stent implantation until hospital discharge (average 1-5 days)
|
Lesion success defined as the attainment of a less than 50% residual stenosis by any percutaneous method.
|
stent implantation until hospital discharge (average 1-5 days)
|
TLF (target lesion failure)
Time Frame: 30 days, 6, 9, 12, 24 and 36 months after index PCI
|
The composite of Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel) or Target Lesion Revascularization (TLR; clinically indicated) (= device oriented endpoint).
|
30 days, 6, 9, 12, 24 and 36 months after index PCI
|
TVF (target vessel failure)
Time Frame: 30 days, 6, 9, 12, 24 and 36 months after index PCI
|
The composite of cardiac death, target vessel myocardial infarction, or clinically-driven target vessel revascularization by percutaneous or surgical methods.
|
30 days, 6, 9, 12, 24 and 36 months after index PCI
|
MACE (major adverse cardiac event)
Time Frame: 30 days, 6, 9, 12, 24 and 36 months after index PCI
|
All-cause death, myocardial infarction (QWMI and NQWMI), emergency coronary artery bypass graft(CABG), or TLR by medical or surgical procedure.
|
30 days, 6, 9, 12, 24 and 36 months after index PCI
|
Stent thrombosis
Time Frame: 30 days, 6, 9, 12, 24 and 36 months after index PCI
|
Incidence of ARC-defined "definite" and "probable" stent thrombosis, and the combined incidence of "definite/probable" stent thrombosis.
|
30 days, 6, 9, 12, 24 and 36 months after index PCI
|
Duration of dual antiplatelet therapy
Time Frame: 12, 24 and 36 months after index PCI
|
Duration of DAPT after index PCI including the reason for interruption and discontinuation.
|
12, 24 and 36 months after index PCI
|
Cerebrovascular accident
Time Frame: 30 days, 6, 9, 12, 24 and 36 months afetr index PCI
|
|
30 days, 6, 9, 12, 24 and 36 months afetr index PCI
|
Procedure success
Time Frame: stent implantation until hospital discharge (average 1-5 days)
|
The attainment of < 50%, residual stenosis of the target lesion and no in-hospital MACE as reported by the physician.
|
stent implantation until hospital discharge (average 1-5 days)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of long-term clinical outcomes due to a difference in follow-up procedure (clinical follow-up or routine angiographic follow-up) after index PCI.
Time Frame: 24 months after index PCI
|
24 months after index PCI
|
|
Evaluation of medical economics
Time Frame: 24 months after index PCI
|
The objectives of this clinical study are to 1) assess the efficacy and safety of RI-ZES at 10 and 22 months (±60 days) after index PCI for routine angiographic FU after index PCI and to 2) investigate its medical costs.
|
24 months after index PCI
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Masato Nakamura, MD, Toho University Medical Center Ohashi Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PROPEL version 3.0 - AEEI
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina